Related Experiment Video
Updated: May 27, 2026

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
Published on: January 12, 2018
17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth
Paul Merlob1, Bracha Stahl, Gil Klinger
1Beilinson Teratology Information Service, Rabin Medical Center, Petah Tikva, Israel.
Abstract:
Use of 17-alpha-hydroxyprogesterone caproate for the prevention of spontaneous preterm birth in women at risk is reviewed. Early studies regarding this topic reached contradicting conclusions, however recent studies showed that weekly injections of 17-alpha-hydroxyprogesterone caproate beginning at 16-20 weeks' gestation resulted in a substantial reduction in the rate of spontaneous recurrent preterm birth. Long-term follow-up of children exposed in-utero to the drug has shown normal growth and development and normal scores for gender specific roles. In conclusion, 17-alpha-hydroxyprogesterone caproate is currently the only drug with sufficient evidence to support its use for prevention of spontaneous recurrent preterm birth.
Related Concept Videos
Intrauterine Drug Delivery Systems
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Teratogenicity
Prodrugs
Prodrugs help overcome...
Birth Control Methods
Drugs for Treatment of Constipation-Predominant IBS
